Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Basal Cell 7Carcinoma, Non-Small-Cell Lung 5Squamous Cell Carcinoma of Head and Neck 4Pancreatic Neoplasms 3Keratosis, Actinic 3Cholangiocarcinoma 3Tongue Neoplasms 2Pleural Diseases 2Non-Muscle Invasive Bladder Neoplasms 2Mycosis Fungoides 2Mesothelioma, Malignant 2Carcinoma, Transitional Cell 2Bile Duct Neoplasms 2Basal Cell Nevus Syndrome 2Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Stomatitis 1Skin Neoplasms 1Sezary Syndrome 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Photosensitivity Disorders 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pain 1Neoplasms 1Lymphoma, T-Cell, Cutaneous 1Lymphoid Interstitial Pneumonia 1Lung Neoplasms 1

Interventions

Gemcitabine 30Mitomycin 25BCG Vaccine 13Docetaxel 10Epirubicin 6erdafitinib 5durvalumab 5dodecyl maltoside 5Radiotherapy 5Cystoscopy 5apaziquone 4ALT-803 4tislelizumab 35-aminolevulinic acid hexyl ester 3viscum album peptide 2pembrolizumab 2disitamab vedotin 2avelumab 2VB4-845 2Therapeutics 2Imiquimod 2Hyaluronic Acid 2Administration, Intravesical 21-phenyl-3,3-dimethyltriazene 2vocimagene amiretrorepvec 1valrubicin 1tremelimumab 1toripalimab 1pirarubicin 1pemigatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Non-Muscle Invasive Bladder Neoplasms × 1-phenyl-3,3-dimethyltriazene × Clear all
NCT03945162 2025-11-24

Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

TheralaseĀ® Technologies Inc.

Phase 2 Recruiting
90 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03053635 2018-08-20

Intravesical Photodynamic Therapy (PDT) in BCG Refractory High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients

TheralaseĀ® Technologies Inc.

Phase 1 Completed
6 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚔